Octagon Capital Advisors LP Taysha Gene Therapies, Inc. Call Options Transaction History
Octagon Capital Advisors LP
- $449 Million
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TSHA
# of Institutions
129Shares Held
150MCall Options Held
48KPut Options Held
7.8K-
Avoro Capital Advisors LLC New York, NY20MShares$33.4 Million0.5% of portfolio
-
Morgan Stanley New York, NY17.6MShares$29.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$19.6 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$18.2 Million0.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.91MShares$14.9 Million0.0% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $80.8M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...